



September 2009

# EP25-A

## Evaluation of Stability of *In Vitro* Diagnostic Reagents; Approved Guideline

This document provides guidance for establishing shelf-life and in-use stability claims for *in vitro* diagnostic reagents such as reagent kits, calibrators, and control products.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in clinical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

## Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Administrative Procedures.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: 610.688.0100  
F: 610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

ISBN 1-56238-706-5  
ISSN 0273-3099

EP25-A  
Vol. 29 No. 20  
Replaces EP25-P  
Vol. 28 No. 32

---

## Evaluation of Stability of *In Vitro* Diagnostic Reagents; Approved Guideline

Volume 29 Number 20

James F. Pierson-Perry  
Sousan S. Altaie, PhD  
Susan J. Danielson, PhD  
Birgitte Lund Jorgensen, PhD  
Bettina Poetsch, PhD  
Rosanne M. Savol, RAC  
Jeffrey E. Vaks, PhD  
Jeffrey Budd, PhD  
Karl De Vore  
Robert Magari, PhD

### Abstract

Clinical and Laboratory Standards Institute document EP25-A—*Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline* provides guidance and regression-based procedures for establishing stability-related claims of *in vitro* diagnostic (IVD) reagents such as reagent kits, calibrators, control products, and sample diluents. This guideline was written primarily for manufacturers and regulatory agencies, but will also be of interest to clinical laboratories. It provides information on the design, implementation, data analysis, and documentation needs for studies to establish and verify shelf life and in-use life of IVD reagents. Additional topics address assessment of product transport conditions on stability and accelerated stability testing.

Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline*. CLSI document EP25-A (ISBN 1-56238-706-5). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2009.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@cls.org](mailto:customerservice@cls.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2009 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline*. CLSI document EP25-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.

### **Proposed Guideline**

December 2008

### **Approved Guideline**

September 2009

ISBN 1-56238-706-5  
ISSN 0273-3099

## Committee Membership

### Area Committee on Evaluation Protocols

**Greg Cooper, CLS, MHA**  
**Chairholder**  
**Bio-Rad Laboratories, Inc.,**  
**QSD Division**  
**Plano, Texas, USA**

**R. Neill Carey, PhD**  
**Vice-Chairholder**  
**Peninsula Regional Medical**  
**Center**  
**Salisbury, Maryland, USA**

John Rex Astles, PhD, FACB  
 Centers for Disease Control and  
 Prevention  
 Atlanta, Georgia, USA

Jeffrey R. Budd, PhD  
 Beckman Coulter, Inc.  
 Chaska, Minnesota, USA

George S. Cembrowski, MD, PhD  
 University of Alberta Hospital  
 Edmonton, Alberta, Canada

David L. Duewer, PhD  
 National Institute of Standards and  
 Technology  
 Gaithersburg, Maryland, USA

Anders Kallner, MD, PhD  
 Karolinska Hospital  
 Stockholm, Sweden

James F. Pierson-Perry  
 Siemens Healthcare Diagnostics  
 Newark, Delaware, USA

Mitchell G. Scott, PhD  
 Washington University School of  
 Medicine  
 St. Louis, Missouri, USA

Lakshmi Vishnuvajjala, PhD  
 FDA Center for Devices and  
 Radiological Health  
 Rockville, Maryland, USA

#### Advisors

David A. Armbruster, PhD,  
 DABCC, FACB  
 Abbott Diagnostics  
 Abbott Park, Illinois, USA

Carl C. Garber, PhD, FACB  
 Quest Diagnostics, Incorporated  
 Lyndhurst, New Jersey, USA

Patricia E. Garrett, PhD  
 SeraCare Life Sciences, Inc.  
 Portland, Maine, USA

Claude Giroud, PhD  
 Bio-Rad Laboratories, Inc.  
 Marnes-La-Coquette, France

Martin H. Kroll, MD  
 Boston Medical Center  
 Boston, Massachusetts, USA

Jan S. Krouwer, PhD  
 Krouwer Consulting  
 Sherborn, Massachusetts, USA

Jacob (Jack) B. Levine, MBA  
 Siemens Healthcare Diagnostics  
 Tarrytown, New York, USA

Kristian Linnet, MD, PhD  
 University of Copenhagen  
 Copenhagen, Denmark

Robert J. McEnroe, PhD  
 Roche Diagnostics Operations, Inc.  
 Indianapolis, Indiana, USA

James H. Nichols, PhD, DABCC,  
 FACB  
 Baystate Medical Center  
 Springfield, Massachusetts, USA

Luann Ochs, MS  
 BD Diagnostics-TriPath  
 Durham, North Carolina, USA

Donald R. Parker, PhD  
 Bayer HealthCare, LLC  
 Elkhart, Indiana, USA

Nils B. Person, PhD, FACB  
 Siemens Healthcare Diagnostics  
 Inc.  
 Flanders, New Jersey, USA

Donald M. Powers, PhD  
 Powers Consulting Services  
 Pittsford, New York, USA

Max Robinowitz, MD  
 FDA Center for Devices and  
 Radiological Health  
 Rockville, Maryland, USA

Michele M. Schoonmaker, PhD  
 Cepheid  
 Sunnyvale, California, USA

Daniel W. Tholen, MS  
 American Association for  
 Laboratory Accreditation  
 Traverse City, Michigan, USA

Jack Zakowski, PhD, FACB  
 Beckman Coulter, Inc.  
 Brea, California, USA

### Subcommittee on Evaluation of Stability of *In Vitro* Diagnostic Reagents

**James F. Pierson-Perry**  
**Chairholder**  
**Siemens Healthcare Diagnostics**  
**Newark, Delaware, USA**

Sousan S. Altaie, PhD  
 FDA Center for Devices and  
 Radiological Health  
 Rockville, Maryland, USA

Susan J. Danielson, PhD  
 Ortho-Clinical Diagnostics  
 Rochester, New York, USA

Birgitte Lund Jorgensen, PhD  
 Radiometer Medical ApS  
 Bronshoj, Denmark

Bettina Poetsch, PhD  
 Roche Diagnostics GmbH  
 Penzberg, Germany

Rosanne M. Savol, RAC  
 Rosebud Consulting  
 Granger, Indiana, USA

Jeffrey E. Vaks, PhD  
 Roche Molecular Diagnostics  
 Pleasanton, California, USA

#### Advisors

Kevin M. Bartko  
 Abbott  
 Abbott Park, Illinois, USA

Jeffrey Budd, PhD  
 Beckman Coulter, Inc.  
 Chaska, Minnesota, USA

**Advisors (Continued)**

Karl De Vore  
Bio-Rad Laboratories, Inc.  
Irvine, California, USA

Chandra P. Jain  
Beckman Coulter, Inc.  
Brea, California, USA

Antje Janssen  
Therapeutic Goods Administration  
Woden, Australia

Robert Magari, PhD  
Beckman Coulter, Inc.  
Miami, Florida, USA

Wadid Sadek, PhD  
Stuarts Draft, Virginia, USA

**Staff**

Clinical and Laboratory Standards  
Institute  
Wayne, Pennsylvania, USA

Lois M. Schmidt, DA  
*Vice President, Standards  
Development and Marketing*

Jane M. Oates, MT(ASCP)  
*Staff Liaison*

Melissa A. Lewis  
*Editor*

Carol DiBerardino, MLA, ELS  
*Assistant Editor*

**Contents**

Abstract.....i

Committee Membership..... iii

Foreword..... vii

1 Scope.....1

2 Standard Precautions.....1

3 Terminology.....1

    3.1 A Note on Terminology .....1

    3.2 Definitions .....2

    3.3 Abbreviations and Acronyms .....4

4 Overview of the Stability Testing Process.....4

    4.1 Operational Definition of Stability .....5

    4.2 Types of Stability Studies .....8

    4.3 Stability Study Design Options.....9

    4.4 The Stability Testing Plan.....9

    4.5 Extension to Qualitative Methods.....11

    4.6 Documentation of Stability Studies .....11

5 Real-time Stability Study Protocol .....11

    5.1 Planning .....11

    5.2 Experimental.....12

    5.3 Data Analysis.....13

6 Real-time Stability Monitoring (Verification) .....15

7 Accelerated Stability Testing .....15

    7.1 Applications of Accelerated Stability Testing .....15

    7.2 Considerations for Planning Temperature-Based Accelerated Stability Studies .....16

    7.3 Analysis of Accelerated Stability Testing Data for Shelf-Life Claims.....17

References.....20

Appendix A. Measurand Drift Analysis Example .....22

Appendix B. Example of Use of Arrhenius Equation With Accelerated Stability Testing Data to Predict Shelf Life of an *In Vitro* Diagnostic Control Product.....24

Appendix C. Determining the Number of Time Points and Repeats for Stability Studies Based on Linear Regression Analysis .....26

Summary of Comments and Subcommittee Responses.....29

Laboratory Failure Sources and CLSI Evaluation Protocols Documents .....36

The Quality Management System Approach .....38

Related CLSI Reference Materials .....39





## Foreword

Stability of an *in vitro diagnostic* (IVD) reagent reflects its ability to maintain consistent performance characteristics over time. Unlike precision, bias, and other common performance attributes, product stability is rarely assessed directly by customer testing. As such, there is increased burden on manufacturers to ensure that stability claims are developed from experimental designs and data analyses that are appropriate for each product's particular requirements and applications.

IVD reagents, in the context of this guideline, represent end-use consumable products sold for the purpose of performing clinical measurements on patient specimens or other samples. Examples of such products are IVD reagent kits and their associated calibrators, controls, sample diluents, and system generic reagents.

Content of this guideline is aligned with European Standard EN 13640:2002—*Stability Testing of In Vitro Diagnostics Reagents*,<sup>1</sup> referenced herein as EN 13640. Two other important internationally recognized guidance documents relative to stability study design and analyses are International Conference on Harmonization (ICH) Q1A (R2)<sup>2</sup> and ICH Q1E.<sup>3</sup> Although these were developed for drugs and drug substances, much of their content is directly relevant to IVD reagents.<sup>4</sup>

## Key Words

Accelerated stability, allowable drift, calibration interval, expiration dating, in-use life, shelf life, stability monitoring, stability plan, transport simulation



## **Evaluation of Stability of *In Vitro* Diagnostic Reagents; Approved Guideline**

### **1 Scope**

This guidance document provides information on the establishment and verification of shelf-life and in-use stability claims for quantitative and qualitative *in vitro* diagnostic (IVD) reagents. It includes background information and typical content to consider when creating a stability testing plan for a particular product, logistics of performing the studies, recommended data analyses, and documentation of stability claims. Additional topics include assessment of product transport conditions on stability claims, stability monitoring (verification), and uses of accelerated stability testing.

The intended users of this guideline are primarily manufacturers of IVD reagents and regulatory agencies. Clinical laboratorians may find this information useful in interpreting commercial product stability claims, as well as for establishing stability attributes of “laboratory-developed test” methods.

This guideline does not address instrument systems, laboratory equipment, software, or patient samples. Stability testing of raw materials or components of reagent kits or consumables is not addressed explicitly. The principles described in this document could, however, be adapted by manufacturers toward that purpose.

### **2 Standard Precautions**

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention.<sup>5</sup> For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to CLSI document M29.<sup>6</sup>

### **3 Terminology**

#### **3.1 A Note on Terminology**

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization of Standardization (ISO), and European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. In light of this, CLSI’s consensus process for development and revision of standards focuses on harmonization of terms to facilitate the global application of standards.